From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy
Immunotherapy has revolutionized the field of cancer therapy. Nanomaterials can further improve the efficacy and safety of immunotherapy because of their tunability and multifunctionality. Owing to their natural biocompatibility, diverse designs, and dynamic self-assembly, peptide-based nanomaterial...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2022.1107600/full |
| _version_ | 1797951385826754560 |
|---|---|
| author | Jing-Jing Du Zhenhong Su Haoyi Yu Sanhai Qin Dongyuan Wang Dongyuan Wang |
| author_facet | Jing-Jing Du Zhenhong Su Haoyi Yu Sanhai Qin Dongyuan Wang Dongyuan Wang |
| author_sort | Jing-Jing Du |
| collection | DOAJ |
| description | Immunotherapy has revolutionized the field of cancer therapy. Nanomaterials can further improve the efficacy and safety of immunotherapy because of their tunability and multifunctionality. Owing to their natural biocompatibility, diverse designs, and dynamic self-assembly, peptide-based nanomaterials hold great potential as immunotherapeutic agents for many malignant cancers, with good immune response and safety. Over the past several decades, peptides have been developed as tumor antigens, effective antigen delivery carriers, and self-assembling adjuvants for cancer immunotherapy. In this review, we give a brief introduction to the use of peptide-based nanomaterials for cancer immunotherapy as antigens, carriers, and adjuvants, and to their current clinical applications. Overall, this review can facilitate further understanding of peptide-based nanomaterials for cancer immunotherapy and may pave the way for designing safe and efficient methods for future vaccines or immunotherapies. |
| first_indexed | 2024-04-10T22:30:50Z |
| format | Article |
| id | doaj.art-89a95989378e4128b7c2a459a5f17b7f |
| institution | Directory Open Access Journal |
| issn | 2296-2646 |
| language | English |
| last_indexed | 2024-04-10T22:30:50Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Chemistry |
| spelling | doaj.art-89a95989378e4128b7c2a459a5f17b7f2023-01-17T05:49:48ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462023-01-011010.3389/fchem.2022.11076001107600From design to clinic: Engineered peptide nanomaterials for cancer immunotherapyJing-Jing Du0Zhenhong Su1Haoyi Yu2Sanhai Qin3Dongyuan Wang4Dongyuan Wang5Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, College of Medicine, Hubei Polytechnic University, Huangshi, ChinaHubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, College of Medicine, Hubei Polytechnic University, Huangshi, ChinaHubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, College of Medicine, Hubei Polytechnic University, Huangshi, ChinaHubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, College of Medicine, Hubei Polytechnic University, Huangshi, ChinaDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, ChinaImmunotherapy has revolutionized the field of cancer therapy. Nanomaterials can further improve the efficacy and safety of immunotherapy because of their tunability and multifunctionality. Owing to their natural biocompatibility, diverse designs, and dynamic self-assembly, peptide-based nanomaterials hold great potential as immunotherapeutic agents for many malignant cancers, with good immune response and safety. Over the past several decades, peptides have been developed as tumor antigens, effective antigen delivery carriers, and self-assembling adjuvants for cancer immunotherapy. In this review, we give a brief introduction to the use of peptide-based nanomaterials for cancer immunotherapy as antigens, carriers, and adjuvants, and to their current clinical applications. Overall, this review can facilitate further understanding of peptide-based nanomaterials for cancer immunotherapy and may pave the way for designing safe and efficient methods for future vaccines or immunotherapies.https://www.frontiersin.org/articles/10.3389/fchem.2022.1107600/fullpeptidevaccinesnanomaterialscancer immunotherapyclinic |
| spellingShingle | Jing-Jing Du Zhenhong Su Haoyi Yu Sanhai Qin Dongyuan Wang Dongyuan Wang From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy Frontiers in Chemistry peptide vaccines nanomaterials cancer immunotherapy clinic |
| title | From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy |
| title_full | From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy |
| title_fullStr | From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy |
| title_full_unstemmed | From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy |
| title_short | From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy |
| title_sort | from design to clinic engineered peptide nanomaterials for cancer immunotherapy |
| topic | peptide vaccines nanomaterials cancer immunotherapy clinic |
| url | https://www.frontiersin.org/articles/10.3389/fchem.2022.1107600/full |
| work_keys_str_mv | AT jingjingdu fromdesigntoclinicengineeredpeptidenanomaterialsforcancerimmunotherapy AT zhenhongsu fromdesigntoclinicengineeredpeptidenanomaterialsforcancerimmunotherapy AT haoyiyu fromdesigntoclinicengineeredpeptidenanomaterialsforcancerimmunotherapy AT sanhaiqin fromdesigntoclinicengineeredpeptidenanomaterialsforcancerimmunotherapy AT dongyuanwang fromdesigntoclinicengineeredpeptidenanomaterialsforcancerimmunotherapy AT dongyuanwang fromdesigntoclinicengineeredpeptidenanomaterialsforcancerimmunotherapy |